REG - Ondine Biomedical - 2025 Full Year Results and Annual Report

Ondine BiomedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nRSD9123Ga&default-theme=true

RNS Number : 9123G  Ondine Biomedical Inc.  04 June 2026

4 June 2026

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or "the Company")

 

2025 Full Year Results and Annual Report

Near-term Phase 3 pivotal study read out; growing international real-world
evidence and commercial traction

 

Ondine Biomedical Inc. (AIM: OBI), a global leader in light-activated
antimicrobial therapies to prevent and treat hospital infections, announces
its audited financial and operational results for year ended 31 December 2025.

Operational Highlights (including post-period end)
Clinical progress

·    Completed patient enrolment in the LANTERN Phase 3 pivotal U.S.
clinical trial across 14 HCA Healthcare Hospitals in the United States and
four Canadian centres. Subject to receipt of final data, top-line results are
expected by the end of Spring 2026.

·    Continued preparations for planned FDA regulatory submissions and
commercial-scale manufacturing readiness following completion of patient
enrolment in the LANTERN study.

·    Reported excellent feasibility pilot study results from the intensive
care unit ("ICU") at Royal Columbian Hospital, demonstrating feasible and safe
implementation of Steriwave in the ICU, significant reduction in nasal
pathogen burden (p<0.01), alongside a 39.5% reduction in observed pneumonia
rates. The results were published in peer-reviewed publication Critical Care
(https://link.springer.com/article/10.1186/s13054-026-06008-7) .

Real-world evidence, healthcare economics and commercial progress

·    Expanded international real-world clinical use with deployments,
pilot programmes, and clinical collaborations increasing 28% year-on-year to
37 hospitals and surgical clinics:

o  Canada: expanded adoption across major Canadian healthcare institutions,
including the University of Ottawa Heart Institute adopting Steriwave as
standard of care for all cardiac surgeries, Interior Health becoming the
second health authority in British Columbia to standardise Steriwave for hip
and knee replacement surgeries, and continued deployment growth across Fraser
Health hospitals and leading cardiac and surgical centres.

o  UK: initiated a Steriwave pilot at Royal Papworth Hospital NHS Foundation
Trust, one of the world's leading cardiothoracic centres, while continuing to
leverage NHS Supply Chain access to support streamlined procurement pathways
across England and Wales.

o  Europe: established clinical collaborations and pilot programmes in
Switzerland, Germany and Spain, including studies evaluating Steriwave in
preoperative nasal decolonisation and ENT surgery pathways.

o  Rest of World: launched the first Steriwave pilot in Mexico at ABC Medical
Center and continued to advance international opportunities, including an
Australian pilot evaluating Steriwave to reduce infection risk in oncology
patients.

·    Reported real-world infection reduction data observed at leading
orthopaedic and spine surgery centres that compared infection rates before and
after introducing Steriwave(®):

o  Mid Yorkshire Teaching NHS Trust: Steriwave implementation was associated
with a 71% reduction in knee and hip arthroplasty surgical infections compared
with another topical nasal antimicrobial agent.

o  Sherbrooke University Hospital, Quebec: Steriwave was associated with a
78% reduction in spine surgery surgical site infections and a 30% reduction in
average hospital length of stay.

Real-world findings are based on observational studies and may be influenced
by multiple factors.

·    A study published by the York Health Economics Consortium (YHEC)
found that using Steriwave prior to major surgery delivers substantial net
cost savings with potential savings to the NHS of £1.49 to £2.38 for every
£1 spent on Steriwave across major surgeries.

Financial Highlights (including post-period end)
Financials (all figures in Canadian dollars)

·    Revenues increased by 29% to $2.6 million (2024: $2.0 million),
driven by new hospital deployments and increased utilisation within existing
accounts.

·    Gross margin was 61% (2024: 64%) with the modest change year-on-year
primarily reflecting the Company's hardware segment, where strategic
investments continue to support customer adoption and market penetration.
Consumables margins improved during the year following the rollout of the
next-generation Nasal Illuminator in Canada.

·    Operating loss was $30 million (2024: $19.4 million), reflecting
increased investment in clinical evidence generation, including conducting the
U.S. Phase 3 pivotal study, FDA audit readiness, and operational
infrastructure to support future growth.

 

Fundraising

·    Successfully secured approximately $5 million in strategic investment
in January 2025, followed by a further c.$19 million in net proceeds from a
fundraising announced in August 2025.

·    Post period-end, successfully completed a further c.$9.2 million
gross proceeds fundraising through a placing and subscription.

Carolyn Cross, CEO of Ondine Biomedical, commented:

"Ondine has used the past year to build with discipline and conviction.
Completion of patient enrolment in our pivotal LANTERN Phase 3 study, marks a
significant milestone in our strategy to bring nasal photodisinfection to the
U.S market. Alongside the trial, our growing body of real-world evidence
continues to demonstrate the potential of Steriwave to reduce infections,
improve patient outcomes and lower healthcare costs.

"With the continued support of our shareholders, we have strengthened our
financial position and taken significant steps towards scaling our
manufacturing capabilities and advancing our FDA submission activities.
Looking ahead, 2026 is expected to be an important year for Ondine as we focus
on delivering the LANTERN clinical results, progressing our regulatory plans
and continuing to execute our growth strategy. We believe the progress
achieved clinically, commercially, financially and operationally over the past
year positions the Company to deliver sustainable growth and long-term value
for shareholders."

Presentation and Live Q&A

Dr. Nicolas Loebel, President and Chief Technology Officer, and Alan Thomas,
Chief Financial Officer, will host a presentation and live Q&A session
relating to the Full Year Results at 16:30 BST (08:30 Pacific time). The
presentation is open to all existing and potential shareholders.

Questions can be submitted pre-event via your Investor Meet Company dashboard
at any time before or during the presentation.

The recording and related slides will be made available after the presentation
on the Company's website: www.ondinebio.com/investors/reports-documentation/
(http://www.ondinebio.com/investors/reports-documentation/) .

Annual Report and AGM

A complete version of the 2025 Annual Report and Accounts ("2025 Annual
Report") can be found here:
http://www.rns-pdf.londonstockexchange.com/rns/9123G_1-2026-6-3.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/9123G_1-2026-6-3.pdf) and is
also being made available to shareholders on the Company's website at
www.ondinebio.com/investors/reports-documentation/
(https://ondinebio.com/investors/reports-documentation/) .

The AGM will be held at 4:00 p.m. BST (8:00 a.m. Pacific Time) on 30 June
2026. The Notice of AGM and Proxy Form are available on the Company's website.

All figures are expressed in Canadian Dollars, unless otherwise stated.

Enquiries:
 Ondine Biomedical Inc.                                www.ondinebio.com (http://www.ondinebio.com/)
 Carolyn Cross, CEO                                    +1 604 669 0555

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                         +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                         +44 (0)20 7418 8900

 5654 & Company (Financial PR and IR Adviser)          ondinebiomedical@5654.co.uk
 Matthew Neal, Chris Gardner, Melissa Gardiner         +44 0791 7800 011

                                                       +44 0775 7697 357

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company focused on the
development of light-activated antimicrobial therapies ('photodisinfection')
for the prevention and treatment of infections, including those associated
with multidrug-resistant organisms.

Ondine's lead product, Steriwave(®), is authorized for nasal decolonisation
in Canada and certain international markets. In the United States, the
technology has been granted Qualified Infectious Disease Product designation
and Fast Track status by the U.S. Food and Drug Administration and recently
completed enrolment in its Phase 3 clinical trial.

The Company has a pipeline of additional photodisinfection products in various
stages of development for application in areas including chronic sinusitis,
ventilator-associated pneumonia, burns and other indications.

U.S. Regulatory Status and Clinical Data Disclaimer

Ondine's light-activated antimicrobial technology, commercially available as
Steriwave(®) in certain jurisdictions, is not approved, cleared, or
commercially available for sale or clinical use in the United States and is
limited by U.S. law to investigational use only.

References to clinical outcomes in this release should be interpreted in the
context of the specific studies or real-world evaluations described and do not
imply regulatory approval for any particular indication.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements
regarding clinical development, regulatory approvals, and potential
indications for the Company's technology. These statements are based on
current expectations and are subject to risks and uncertainties that may cause
actual results to differ materially.

Such risks include clinical trial outcomes, regulatory decisions, and
commercial factors. Readers are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date of this
announcement. The Company undertakes no obligation to update them except as
required by applicable law, including the AIM Rules for Companies and UK
Market Abuse Regulation.

 

 

Chairman's Statement: Foundations for a Pivotal Year

 

In 2025, Ondine Biomedical continued to advance its long-term strategy of
redefining infection prevention through non-antibiotic solutions.
Healthcare-associated infections remain one of the most persistent and costly
challenges facing global healthcare systems, compounded by the accelerating
impact of antimicrobial resistance. Against this backdrop, the need for
effective, scalable alternatives to traditional approaches has never been
greater.

 

Ondine is focused on establishing photodisinfection as a foundational
technology in infection prevention. Our light-activated,
non-resistance-forming approach is designed to align with the evolving
priorities of healthcare systems worldwide - improving patient outcomes,
increasing surgical capacity, and reducing the economic burden associated with
avoidable infections. This positions the Company at the intersection of two
powerful drivers of change: the global response to antimicrobial resistance
and the growing demand for more efficient, outcome-focused care delivery.

 

Over the past year, we have continued to build the clinical, regulatory, and
commercial foundations necessary to support long-term growth. Our strategy is
centred on generating high-quality evidence, engaging with leading
institutions, and advancing regulatory pathways in key markets, particularly
the United States. At the same time, we are expanding awareness and acceptance
of photodisinfection through scientific and clinical engagement, with
increasing recognition of its role within modern infection control protocols.

 

A central pillar of this strategy is the LANTERN Phase 3 pivotal study,
conducted across 18 hospitals in two countries and involving more than 5,000
patients. This landmark trial, supported by HCA Healthcare and delivered in
partnership with its expert research team, represents a defining moment for
the Company. As the world's first nasal photodisinfection-based crossover
study, it has been designed to provide the level of evidence required to
support regulatory approval and broad clinical adoption in the United States.

 

With top-line results anticipated in Spring 2026, we are focused on the next
phase of our development, including preparation for FDA submission and
subsequent commercial expansion. We believe successful completion of this
process will not only enable entry into the U.S. market but also serve as a
catalyst for wider global adoption and the continued development of Ondine's
broader pipeline of photodisinfection applications.

 

Looking ahead, our priority is to translate our clinical progress into
sustainable commercial growth. This includes deepening partnerships with
healthcare providers, demonstrating economic value at scale, and ensuring that
our technology can be readily integrated into standard clinical practice. As
healthcare systems continue to seek solutions that address both clinical
outcomes and cost pressures, we are confident that Ondine is well positioned
to play a meaningful role in shaping the future of infection prevention.

 

On behalf of the Board, I would like to thank our management team, partners,
and shareholders for their continued commitment and support as we build the
foundations for long-term success.

 

The Honourable Jean Charest

Chairman

4 June 2026

 

 

 

CEO Statement: Preparing for Global Impact

 

In 2025, Ondine Biomedical maintained a disciplined focus on execution, with a
clear objective: to translate our technology and clinical progress into a
scalable, high-impact business. We concentrated our efforts on building the
clinical and regulatory foundations necessary for U.S. market entry, while at
the same time shaping a commercial model designed for sustainable growth and
broad adoption.

 

Healthcare-associated infections remain a major driver of cost and capacity
constraints for health systems, with billions of dollars spent each year on
preventable complications and their consequences. Each surgery has an embedded
"infection tax" of up to $1,000 before lost surgical capacity and quality of
life considerations are quantified. Alongside clinical data, we are generating
health economic evidence to quantify the potential cost, capacity and patient
outcome benefits of nasal photodisinfection compared with current standard of
care.

 

As antimicrobial resistance continues to erode the effectiveness of
traditional antibiotics, providers are actively seeking practical,
non-antibiotic solutions that can improve outcomes, protect capacity, and
support more efficient care delivery. Ondine's photodisinfection platform
addresses this need through a light-activated antimicrobial approach that does
not rely on antibiotics or generate resistance and can be integrated at
critical points in the patient journey. Our real-world results suggest that
nasal photodisinfection offers improved outcomes for both patients and
healthcare systems.

 

Our central operational priority in 2025 was the successful execution of the
LANTERN Phase 3 pivotal trial, which underpins our U.S. regulatory strategy.
Conducted across 18 hospitals in two countries and involving more than 5,000
patients, LANTERN represents the most significant clinical investment in the
Company's history. We are deeply grateful to HCA Healthcare and its clinical
research group, HRI, for their leadership, expertise, and commitment in
managing this large-scale, complex study. We would also like to thank the
experienced research teams at the four Canadian hospitals who supported our
trial with their expertise and their patient access as well as healthcare
system and population diversity. This collaboration has been instrumental in
bringing the LANTERN trial to completion.

 

With top-line LANTERN results anticipated in Spring 2026, our focus is now on
ensuring that we are ready to move decisively once data are available. This
includes completing the clinical study report, finalising the remaining
components of our planned New Drug Application to the U.S. Food and Drug
Administration, and aligning our organisation and resources around a clear
path to launch, subject to regulatory approval.

 

In parallel with LANTERN, we continued to broaden the clinical and commercial
footprint of Steriwave. Pilot programmes and evaluations across multiple key
geographies and care settings are being undertaken selectively to build the
right partnerships. Spanning new surgical and distribution pathways as well as
early work in high-risk environments such as intensive care, these pilots
support our land-and-expand strategy. With this approach, we are integrating
direct experience and real-world knowledge to optimise our commercial
strategies.

 

The intensive care unit (ICU) will be an important market for nasal
photodisinfection given the 12-15% infection rates in these fragile patients.
In 2025, the AIM Royal Columbian Hospital research group successfully
conducted and completed the world's first clinical study of nasal
photodisinfection in the ICU. This investigator-initiated pilot study
demonstrated patient safety and the feasibility of integrating Steriwave into
ICU workflows and generated strong evidence of nasal pathogen reduction in
critically ill patients, confirming our belief that nasal photodisinfection
can significantly improve outcomes in the ICU. The study, now published in
Critical Care, also showed an observed reduction in hospital-acquired
pneumonia, a leading cause of morbidity, mortality, and cost in critical care
settings.

 

With an expanding set of indications in mind, we deliberately target leading
institutions and specific high-value use cases where the clinical and economic
impact of infection prevention is most visible. Over time, we work to expand
utilisation across additional departments, procedures, and indications as
confidence and experience grow. In this way, we hope to expand the network of
photodisinfection users to build awareness and regional endorsement.

 

This pilot-driven approach serves several purposes. It generates real-world
evidence that complements our clinical trial data, building confidence among
clinicians and administrators. It deepens relationships with hospital
partners, creating internal advocates who understand both the clinical impact
and operational practicality of photodisinfection. This also establishes
initial commercial beachheads from which we can grow sales as health systems
see the benefits in reduced complications, increased throughput, and more
efficient use of existing infrastructure.

 

To support this strategy, we have continued to strengthen our operational
capabilities. Investments in manufacturing and supply, including enhanced
control over key components of our photosensitizer delivery, are intended to
support reliable scaling as demand grows. At the same time, we are refining a
service-led commercial model that simplifies hospital adoption, emphasising
integration into existing workflows, staff training, and data-driven
demonstration of value, as we prepare for broader rollout.

 

While our current installed base and revenue remain at an early-stage relative
to the scale of the opportunity, there is significant potential for long-term
growth if clinical, regulatory and commercial milestones continue to be
achieved. More than 300 million surgical procedures are performed each year
worldwide, and infection prevention is an increasingly strategic priority for
health systems working to manage cost, capacity, and risk. We believe that a
combination of strong clinical data, compelling real-world evidence, and a
targeted land-and-expand commercial strategy leveraging our existing hospital
and healthcare system relationships can position Ondine to capture a
meaningful share of this large and growing market over time. Success with the
first photodisinfection application will help to accelerate the
commercialization of our other treatment and prevention products in our
pipeline.

 

Looking ahead, 2026 is expected to be a defining year for the Company. Our
priorities are clear: deliver the LANTERN clinical results, advance our FDA
submission, and build up the operational and commercial capabilities required
for launch and subsequent scale-up. We remain committed to disciplined capital
allocation, evidence-led decision-making, and a sharp focus on execution.

 

We would like to thank our dedicated employees and consultants, our numerous
clinical partners, and our loyal shareholders for their continued trust and
support of our efforts to bring our lifesaving technologies to global
healthcare systems. We remain focused on translating our scientific and
clinical progress into durable, long-term value for all stakeholders.

 

Carolyn Cross

Chief Executive Officer

4 June 2026

 

 

 

Our Strategy: Unlocking the Full Potential of Our Proprietary Platform

 

Foundations for scalable growth

Ondine's strategy is focused on realising the full potential of its
proprietary photodisinfection platform across global healthcare markets,
starting with Steriwave. Steriwave serves as a strategic entry point into
healthcare systems, creating opportunities to expand into additional
indications, departments, and future platform applications.

 

In 2025, we made a deliberate decision to prioritise clinical evidence
generation to strengthen the foundation for continued adoption and future
expansion, while maintaining targeted commercial activity. This included
investment in the LANTERN Phase 3 study, the first ICU feasibility study of
Steriwave, and collaborations with leading health care institutions to
generate real-world clinical and health economic evidence.

 

Together, these initiatives strengthened Ondine's clinical, commercial and
operational foundations. They support the Company's land-and-expand strategy,
help build confidence among clinicians and healthcare administrators, and
provide a stronger platform for future growth as Ondine prepares for the next
stages of U.S. regulatory engagement, commercial adoption and global scale-up.

 

Commercial adoption

During 2025 and post-period, Ondine continued to expand its international
real-world clinical footprint, with deployments, pilot programmes and clinical
collaborations increasing by 28% year-on-year to 37 hospitals and surgical
clinics. These sites support workflow integration, local clinical adoption and
the generation of real-world evidence for Steriwave.

 

Our commercial adoption is driven by a disciplined land-and-expand model
designed to establish high-credibility footholds with key hospital systems. By
targeting initial deployments with clinicians focused on improving patient
outcomes, we secure the early-stage evidence and local advocacy required for
broader rollout.

 

Throughout 2025, we concentrated on establishing these strategic beachheads,
prioritising workflow integration and evidence generation.

 

In Canada, adoption expanded across major healthcare institutions, including
the University of Ottawa Heart Institute adopting Steriwave as standard of
care for all cardiac surgeries, Interior Health becoming the second health
authority in British Columbia to standardise Steriwave for hip and knee
replacement surgeries, and continued deployment growth across Fraser Health
hospitals and other leading cardiac and surgical centres. The technology was
also deployed for the first time in an intensive care unit at Royal Columbian
Hospital, extending its application beyond traditional surgical pathways.

 

In the United Kingdom, Steriwave was integrated into cardiac surgical care
pathways through a pilot programme at Royal Papworth Hospital NHS Foundation
Trust, supported by Ondine's distribution partner Mölnlycke Health Care. The
Company also continued to leverage its NHS Supply Chain listing to support
streamlined procurement pathways and increase visibility among NHS
organisations across England and Wales.

 

Across Europe, Ondine expanded clinical collaborations and pilot programmes,
including an ENT pilot at LMU University Hospital Munich, an independent study
at University Hospital Zurich, and deployment supporting ENT surgery pathways
in Spain. Beyond these markets, Steriwave was introduced through a first
hospital pilot at ABC Medical Center in Mexico City and is being used in
oncology patients at The Mater Hospital in Sydney, Australia, further
expanding its application across new geographies and patient populations.

 

The evidence generated during 2025 and post-period further strengthened the
case for broader adoption. Independent findings reported significant
reductions in surgical site infections across orthopaedic and spine surgery
pathways, including a 71% reduction in knee and hip arthroplasty infections at
Mid Yorkshire Teaching NHS Trust and a 78% reduction in spine surgical site
infections at Université de Sherbrooke with a 30% reduction in average
hospital length of stay. In parallel, analysis by the York Health Economics
Consortium (YHEC) confirmed that using Steriwave prior to major surgery can
deliver substantial net cost savings, with potential savings of £1.49-£2.38
for every £1 invested. Together, this evidence provides further validation of
Steriwave's clinical and economic value and support broader adoption by
healthcare providers and administrators.

 

This methodical approach cultivates clinical champions and high-profile
reference sites, creating a scalable foundation to expand across new
departments, geographies and use cases including expansion to additional areas
within the same institution, expansion into additional hospitals and regions,
and expansion into new use cases.

 

Preparation for U.S. market entry

In 2025, Ondine directed the majority of its financial, human, and operational
resources to the execution of its LANTERN Phase 3 pivotal study. This
large-scale, private/public multicentre cross-over study conducted across two
countries represents a significant milestone for Ondine, and is a key
component of Ondine's regulatory submission to the U.S. Food and Drug
Administration (FDA) for access to the U.S. market.

 

Patient enrolment in the LANTERN study was completed post-period, with 5,188
patients enrolled across 14 HCA Healthcare hospitals in the United States and
four hospitals in Canada. Subject to receipt of final data, the Company
remains on track to report top-line results in Spring 2026 and is advancing
the activities required to support its planned NDA pathway, including
regulatory engagement, and related manufacturing and commercial planning.

 

Operational readiness and scale-up

Ondine's ability to scale is driven by the deliberate build-out of its
operational and organisational infrastructure. In 2025, the Company
strengthened manufacturing, supply chain, systems, and talent frameworks to
support demand and consistent execution. These foundations enable complex
clinical delivery and support transition to large-scale commercial deployment.

 

During 2025 and post-period, the Company continued to advance its in-house
manufacturing capabilities through dedicated equipment, facility upgrades and
system improvements, including the installation and validation of automated
fill-and-finish equipment to increase capacity, improve production control and
support lower cost of goods over time. Ondine also continued to enhance its
Quality Management System through the consolidation and digitisation of
quality processes, supporting a transition to a predominantly paperless
environment by the end of 2026 and improving operational efficiency. In
parallel, the Company introduced formal Sales and Operations Planning
processes and further strengthened supply chain capabilities to improve demand
forecasting, supply alignment and readiness for future global scale-up.

 

Financial Review

 

Ondine's financial priorities during 2025 were focused on advancing clinical
development, supporting targeted commercial activity, and strengthening
operational infrastructure. The Company directed the majority of its
investment toward its pivotal Phase 3 clinical trial, reflecting a deliberate
emphasis on building clinical validation ahead of key regulatory milestones as
a driver of long-term value. During the year, the Company raised c. $24
million to support these clinical priorities with the support of its long-term
shareholders and other investors.

 

In parallel, Ondine made targeted investments in manufacturing and operational
infrastructure to support future scalability, including dedicated
manufacturing equipment, preparatory work to enable in-house fill-and-finish
capability, and upgrades to internal systems to improve production efficiency,
quality and supply chain resilience.

 

This disciplined allocation of capital reflects a clear strategy to prioritise
clinical progress and operational readiness, positioning the Company for its
next phase of growth as it approaches key clinical and regulatory milestones.

 

Revenue

Revenue increased by 29% to $2.6 million (2024: $2.0 million), driven by new
hospital deployments and increased utilisation within existing accounts. Gross
margin was 61% (2024: 64%), with the modest change year-on-year primarily
reflecting the Company's hardware segment, where strategic investments
continue to support customer adoption and market penetration. Consumable's
margins improved during the year following the rollout of the Company's
next-generation Nasal Illuminator in Canada.

 

Research and development expenditure

Research and development expenses totalled $21.2 million (2024: $9.2 million),
of which $16.6 million was attributable to the LANTERN Phase 3 clinical trial.
The majority of total projected trial costs have been incurred as of 2025,
with the study now near completion.

 

The Company notes that Phase 3 clinical trials in the pharmaceutical industry
typically involve per-patient costs in the tens of thousands of dollars and
can result in total trial costs in the hundreds of millions for studies of
comparable size and scale. The Company's investment demonstrates its ability
to execute a large-scale clinical trial with capital significantly below that
typically associated with studies of this size.

 

In addition, the Company completed its first ICU pilot study during the year,
demonstrating a significant reduction in nasal bacterial load in critically
ill patients. The study was funded through equity-based arrangements, allowing
the Company to advance clinical evidence generation while preserving cash
resources. The Company also supported clinical and commercial pilot programmes
across multiple geographies.

 

General and administrative expenses

General and administrative expenses decreased by 12% to $8.7 million (2024:
$9.9 million), reflecting ongoing efforts to optimise the cost base while
maintaining core capabilities.

 

Marketing and sales expenses

Marketing and sales expenses remained stable at $1.1 million (2024: $1.1
million), reflecting the Company's prioritisation of clinical development over
near-term revenue expansion. Commercial activity remained focused on building
a foundation for future growth, including expanding the Company's installed
base, working closely with distribution partners in early-stage market
development, and onboarding and supporting Phase 3 clinical trial sites.

 

Liquidity, cash and cash equivalents

As at December 31, 2025, the Company held cash of $10.6 million (2024: $9.9
million). Net cash used in operating activities was $23.8 million (2024: $15.5
million), primarily driven by investment in the Phase 3 clinical trial. During
the year, the Company secured $24.2 million in financing (2024: $21.7
million), supporting continued operations and strategic priorities.

 

The Company continues to manage its capital resources carefully, aligning
expenditure with strategic priorities and maintaining focus on efficiency and
disciplined execution.

 

Post-period fundraise

Post period, Ondine raised $8.6 million in net cash from a £5.0 million gross
fundraise ($9.2 million), with extensive support from existing shareholders.

 

Alan Thomas

Chief Financial Officer

4 June 2026

 

http://www.rns-pdf.londonstockexchange.com/rns/9123G_1-2026-6-3.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/9123G_1-2026-6-3.pdf)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FR UPUUUQUPQGRW



            Copyright 2019 Regulatory News Service, all rights reserved